Ronnie Shapira-Frommer
Overview
Explore the profile of Ronnie Shapira-Frommer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
75
Citations
10432
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lidar M, Rimar D, David P, Jacoby E, Shapira-Frommer R, Itzhaki O, et al.
Ann Rheum Dis
. 2025 Feb;
84(2):370-372.
PMID: 39919909
No abstract available.
2.
Dummer R, Robert C, Scolyer R, Taube J, Tetzlaff M, Menzies A, et al.
Nat Med
. 2025 Jan;
31(1):144-151.
PMID: 39775043
Neoadjuvant immunotherapies have shown antitumor activity in melanoma. Substudy 02C of the global, rolling-arm, phase 1/2, adaptive-design KEYMAKER-U02 trial is evaluating neoadjuvant pembrolizumab (anti-PD-1) alone or in combination, followed by...
3.
Shapira-Frommer R, Niu J, Perets R, Peters S, Shouse G, Lugowska I, et al.
Future Oncol
. 2024 Sep;
20(27):1983-1991.
PMID: 39230120
Vibostolimab, a humanized IgG1 monoclonal antibody, blocks the interaction between TIGIT and its ligands, preventing the immunosuppressive effects of TIGIT. The addition of vibostolimab to the PD-1 inhibitor pembrolizumab has...
4.
Tewari K, Colombo N, Monk B, Dubot C, Caceres M, Hasegawa K, et al.
JAMA Oncol
. 2023 Dec;
10(2):185-192.
PMID: 38095881
Importance: The KEYNOTE-826 randomized clinical trial showed statistically significant and clinically meaningful survival benefits with the addition of pembrolizumab to chemotherapy with or without bevacizumab in patients with persistent, recurrent,...
5.
Weinstein-Marom H, Blokon-Kogan D, Levi-Mann M, Katzman C, Shalev S, Zaitsev M, et al.
Methods Mol Biol
. 2023 Dec;
2748:167-186.
PMID: 38070115
Genetic modification of tumor-infiltrating lymphocytes (TILs) or circulating T cells has become an important avenue in cancer therapy. Here we describe a comprehensive method for establishing and expanding TIL cultures...
6.
Monk B, Toita T, Wu X, Vazquez Limon J, Tarnawski R, Mandai M, et al.
Lancet Oncol
. 2023 Dec;
24(12):1334-1348.
PMID: 38039991
Background: Concurrent chemoradiotherapy has been the standard of care for locally advanced cervical cancer for over 20 years; however, 30-40% of treated patients have recurrence or progression within 5 years....
7.
Grynberg S, Vered M, Shapira-Frommer R, Asher N, Ben-Betzalel G, Stoff R, et al.
J Natl Cancer Inst
. 2023 Nov;
116(4):539-546.
PMID: 37966914
Background: Ameloblastoma is a rare odontogenic neoplasm frequently located in the mandible. Standard treatment involves radical bone resection and immediate reconstruction, causing functional, aesthetic, and psychological impairments. The BRAF V600E...
8.
Monk B, Colombo N, Tewari K, Dubot C, Caceres M, Hasegawa K, et al.
J Clin Oncol
. 2023 Nov;
41(36):5505-5511.
PMID: 37910822
JCO The phase III, double-blind KEYNOTE-826 trial of pembrolizumab 200 mg or placebo once every 3 weeks for up to 35 cycles plus platinum-based chemotherapy, with or without bevacizumab, showed...
9.
Arend R, Monk B, Shapira-Frommer R, Haggerty A, Alvarez E, Amit A, et al.
J Clin Oncol
. 2023 Oct;
42(2):170-179.
PMID: 37906726
Purpose: To evaluate the addition of ofranergene obadenovec (ofra-vec, VB-111), a novel gene-based anticancer targeted therapy, to once a week paclitaxel in patients with recurrent platinum-resistant ovarian cancer (PROC). Methods:...
10.
Ledermann J, Shapira-Frommer R, Santin A, Lisyanskaya A, Pignata S, Vergote I, et al.
Gynecol Oncol
. 2023 Oct;
178:119-129.
PMID: 37862791
Objective: This prespecified exploratory analysis evaluated the association of gene expression signatures, tumor mutational burden (TMB), and multiplex immunohistochemistry (mIHC) tumor microenvironment-associated cell phenotypes with clinical outcomes of pembrolizumab in...